■为了探索美国从2000年到2020年的前列腺癌发病率趋势是否因种族和民族而异,年龄和肿瘤分期;探讨2020年由于COVID-19大流行封锁的影响,前列腺癌发病率变化的种族差异;并确定是否有任何高危人群可以作为预防的目标。
■我们在监测的17个登记册中确定了2000-2020年1,098,349名男性在年龄≥20岁时被诊断为偶发前列腺癌。流行病学,和美国的最终结果(SEER)计划;其中,778,437是非西班牙裔白人,155,111名非西班牙裔黑人,4,200名美洲印第安人和阿拉斯加原住民(AIAN),55,267名非西班牙裔亚洲人/太平洋岛民,和105,334个西班牙裔。
■年龄调整后的前列腺癌发病率在黑人中最高(每100,000名男性中302.6例),其次是白人(186.6),西班牙裔(153.2),AIAN(108.5),和亚洲人(104.9)。从2000年到2013年,所有种族男性的年龄调整后的前列腺癌发病率急剧下降。然而,从2014年到2020年,年龄调整后的前列腺癌发病率上升,其中黑人和白人的发病率上升趋势更为明显,在亚洲人中更讨人喜欢,在AIAN和西班牙裔。在所有年份都有地方或地区阶段的男性中,黑人的前列腺癌发病率明显较高,但西班牙裔明显较低,AIAN,与白人相比,亚洲人。在2007-2013年的男性中,黑人(比率:2.22,95%CI:2.06-2.38)和西班牙裔(1.16,1.06-1.25)的远隔期前列腺癌的风险在统计学上显着升高,AIAN没有显著差异(1.30,0.92-1.76),但与白人相比,亚洲人(0.73,0.66-0.82)仍然明显较低。从2019年到2020年,前列腺癌发病率下降,可能是由于COVID-19大流行封锁对2020年获得医疗服务的影响。黑人的整体前列腺癌发病率从2019年的277.4降至2020年的237.0,每10万人中下降40.4例。白人从164.2到143.3的20.9,西班牙裔的16.8从124.8到108.0,AIAN从101.7到86.8的14.9,亚洲人从88.4到75.8的12.6。
■从2000年到2013年,所有种族男性前列腺癌发病率的下降趋势具有统计学意义。从2014年到2020年,前列腺癌的发病率不断上升。年龄调整后的前列腺癌发病率在黑人中最高,其次是白人,西班牙裔,AIAN,亚洲人,无论年龄组,肿瘤分期,和时间段。还需要监测和调查COVID-19大流行季节期间和之后的前列腺癌发病率趋势。
UNASSIGNED: To explore whether prostate cancer incidence trends from 2000 to 2020 in the United States differed by race and ethnicity, age and tumor stage; to explore racial differences in prostate cancer incidence change due to the impact of COVID-19 pandemic lockdown in 2020; and to determine if there is any high-risk population that can be targeted for prevention.
UNASSIGNED: We identified 1,098,349 men who were diagnosed with incident prostate cancer at age ≥20 in 2000-2020 in 17 registries of the Surveillance, Epidemiology, and End Results (SEER) program in the United States; of whom, 778,437 were non-Hispanic whites, 155,111 non-Hispanic blacks, 4,200 American Indians and Alaska Natives (AIAN), 55,267 non-Hispanic Asians/Pacific Islanders, and 105,334 Hispanics.
UNASSIGNED: Age-adjusted incidence rate of prostate cancer was the highest in blacks (302.6 cases per 100,000 men), followed by whites (186.6), Hispanics (153.2), AIAN (108.5), and Asians (104.9). Age-adjusted prostate cancer incidence rates dramatically decreased from 2000 to 2013 for all ethnic men. However, age-adjusted prostate cancer incidence rates increased from 2014 to 2020, in which the increasing incidence trend looked sharper in blacks and whites, flatter in Asians, and leveled in AIAN and Hispanics. Among men with local or regional stages across all years, prostate cancer incidence rate was significantly higher in blacks, but significantly lower in Hispanics, AIAN, and Asians as compared to whites. Among men in 2007-2013, the risk of distant stage prostate cancer was statistically significantly elevated in blacks (rate-ratio: 2.22, 95% CI: 2.06-2.38) and Hispanics (1.16, 1.06-1.25), not significantly different in AIAN (1.30, 0.92-1.76), but still significantly lower in Asians (0.73, 0.66-0.82) as compared to whites. There was a drop of prostate cancer incidence from 2019 to 2020 likely due to the impact of COVID-19 pandemic lockdown on the access to medical care in 2020. Overall prostate cancer incidence rate decreased by 40.4 cases per 100,000 population from 277.4 in 2019 to 237.0 in 2020 for blacks, 20.9 from 164.2 to 143.3 for whites, 16.8 from 124.8 to 108.0 for Hispanics, 14.9 from 101.7 to 86.8 for AIAN, and 12.6 from 88.4 to 75.8 for Asians.
UNASSIGNED: The decreasing trend of prostate cancer incidence from 2000 to 2013 was statistically significant for all ethnic men. There was an increasing prostate cancer incidence from 2014 to 2020. Age-adjusted incidence rate of prostate cancer was the highest in blacks, followed by whites, Hispanics, AIAN, and Asians, regardless of age groups, tumor stages, and time periods. There will also be a need to monitor and investigate the prostate cancer incidence trend during and after COVID-19 pandemic season.